Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

SARS: Systematic Review of Treatment Effects

Open access

Abstract

BACKGROUND: The SARS outbreak of 2002-2003 presented clinicians with a new, life-threatening disease for which they had no experience in treating and no research on the effectiveness of treatment options. The World Health Organization (WHO) expert panel on SARS treatment requested a systematic review and comprehensive summary of treatments used for SARS-infected patients in order to guide future treatment and identify priorities for research. METHODS AND FINDINGS: In response to the WHO request we conducted a systematic review of the published literature on ribavirin, corticosteroids, lopinavir and ritonavir (LPV/r), type I interferon (IFN), intravenous immunoglobulin (IVIG), and SARS convalescent plasma from both in vitro studies and in SARS patients. We also searched for clinical trial evidence of treatment for acute respiratory distress syndrome. Sources of data were the literature databases MEDLINE, EMBASE, BIOSIS, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to February 2005. Data from publications were extracted and evidence within studies was classified using predefined criteria. In total, 54 SARS treatment studies, 15 in vitro studies, and three acute respiratory distress syndrome studies met our inclusion criteria. Within in vitro studies, ribavirin, lopinavir, and type I IFN showed inhibition of SARS-CoV in tissue culture. In SARS-infected patient reports on ribavirin, 26 studies were classified as inconclusive, and four showed possible harm. Seven studies of convalescent plasma or IVIG, three of IFN type I, and two of LPV/r were inconclusive. In 29 studies of steroid use, 25 were inconclusive and four were classified as causing possible harm. CONCLUSIONS: Despite an extensive literature reporting on SARS treatments, it was not possible to determine whether treatments benefited patients during the SARS outbreak. Some may have been harmful. Clinical trials should be designed to validate a standard protocol for dosage and timing, and to accrue data in real time during future outbreaks to monitor specific adverse effects and help inform treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0030343

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Process of Study Exclusion for Each Objective Category
Figure 1 Process of Study Exclusion for Each Objective CategoryCC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 30

  1. Ksiazek, 2003, N Engl J Med, 348, 1953
  2. Peiris, 2003, Lancet, 361, 1319
  3. Drosten, 2003, N Engl J Med, 348, 1967
  4. Peiris, 2003, N Engl J Med, 2003, 2431
  5. Leung, 2004, Ann Intern Med, 141, 662
  6. Fowler, 2003, JAMA, 290, 367
  7. Poutanen, 2003, N Engl J Med, 348, 1995
  8. Lee, 2003, N Engl J Med, 348, 1986
  9. Morgenstern, 2005, Biochem Biophys Res Commun, 326, 905
  10. Chen, 2004, J Clin Virol, 31, 69
  11. Knowles, 2003, Clin Infect Dis, 37, 1139
  12. Booth, 2003, JAMA, 289, 2801
  13. Sung, 2004, Thorax, 59, 414
  14. Wong, 2003, JAMA, 290, 2663
  15. Yamamoto, 2004, Biochem Biophys Res Commun, 318, 719
  16. Chan, 2003, Hong Kong Med J, 9, 399
  17. Chu, 2004, Thorax, 59, 252
  18. Lee, 2004, J Clin Virol, 31, 304
  19. Lee, 2004, Clin Infect Dis, 39, 1247
  20. Xiao, 2004, Zhonghua Nei Ke Za Zhi, 43, 179
  21. Li, 2004, Zhonghua Yi Xue Za Zhi, 84, 1348
  22. Bernard, 1987, N Engl J Med, 317, 1565
  23. Weigelt, 1985, Arch Surg, 120, 536
  24. Meduri, 1998, JAMA, 280, 159
  25. Scagnolari, 2004, Antivir Ther, 9, 1003
  26. Sainz, 2004, Virology, 329, 11
  27. Wu, 2003, Zhonghua Nei Ke Za Zhi, 42, 453
  28. Li, 2003, Zhonghua Er Ke Za Zhi, 41, 574
  29. Hwang, 2005, Mod Pathol, 18, 1
  30. Wang, 2003, N Engl J Med, 349, 507

Cited by

See all 1,217

Metadata

Authors
Stockman, L. J., Bellamy, R., & Garner, P.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • James Cook University Hospital (GB)
  • Liverpool School of Tropical Medicine (GB)
Corresponding author
Stockman, Lauren J
Venue
PLoS Medicine
Published
2006-09-12
Volume
3
Issue
9
Pages
e343
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2054076340
Cited by
1,217
References
31
Citations by year
2026: 3 · 2025: 9 · 2024: 34 · 2023: 58 · 2022: 92 · 2021: 254 · 2020: 579 · 2019: 10 · 2018: 3 · 2017: 9 · 2016: 28 · 2015: 16 · 2014: 20 · 2013: 19 · 2012: 8
FWCI
1.94
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, public-domain)
  • Europe PMC (PubMed Central) (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (publishedVersion)
  • LSTM Online Archive (Liverpool School of Tropical Medicine) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Department for International Development
  • Centers for Disease Control and Prevention
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
Keywords
SARS, SARS-CoV, antiviral therapy, ribavirin, corticosteroids, type I interferon, intravenous immunoglobulin, convalescent plasma, acute respiratory distress syndrome, treatment efficacy, adverse effects, clinical trial design
MeSH terms
Disease Outbreaks, Humans, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS: Systematic Review of Treatment Effects. https://app.cochat.ai/papers/10.1371/journal.pmed.0030343
The paper
Stockman, L. J., Bellamy, R., & Garner, P. (2006). SARS: Systematic Review of Treatment Effects. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0030343

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.